Hospital
Freeport Memorial Hospital
Freeport Memorial Hospital was paid $1.40M by Medicaid between Jan 2018 and Jul 2020, across 86 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 49% of everything it billed.
33Billing provider infoFREEPORT MEMORIAL HOSPITAL
FREEPORT, IL 61032
FREEPORT, IL 61032
33aNPI1447228788assigned 03/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.40M
24GClaims84,865
24DCodes billed86
24AFirst – last monthJan 2018 – Jul 2020
Compared with peers
Next to other General Acute Care Hospital providers in Illinois
Rank by total paid#39 of 129
Median peer was paid$547K
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MALAS, JOSEPH controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,670 | $292K | |
| 2019 | 53,731 | $786K | |
| 2020 | 18,464 | $320K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 49% | 8,825 | 2,008 | $681K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.1% | 2,958 | 667 | $99K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 7.0% | 1,361 | 673 | $97K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.5% | 4,953 | 2,422 | $62K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.2% | 939 | 276 | $45K |
| 80053 | Comprehensive metabolic panel | 3.0% | 8,489 | 4,043 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.9% | 468 | 287 | $40K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.6% | 2,245 | 1,143 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.6% | 2,237 | 1,139 | $36K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.3% | 467 | 202 | $32K |
| 87631 | 1.5% | 207 | 89 | $21K | |
| 80081 | 1.5% | 372 | 164 | $21K |
74 more codes
| 83655 | 1.3% | 1,744 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 289 | $16K |
| 87081 | 1.0% | 3,195 | $14K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 681 | $14K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 441 | $14K |
| 97161 | <1% | 388 | $13K | |
| 87186 | <1% | 1,301 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,874 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,066 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,424 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,690 | $7K |
| 80305 | <1% | 1,526 | $6K | |
| 87070 | <1% | 1,758 | $6K | |
| 97162 | <1% | 145 | $4K | |
| 80061 | Lipid panel | <1% | 4,736 | $3K |
| 88142 | <1% | 1,674 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 152 | $3K |
| 82607 | <1% | 565 | $2K | |
| 84146 | <1% | 226 | $2K | |
| 84702 | <1% | 264 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 38 | $2K |
| 85027 | <1% | 1,651 | $2K | |
| 86038 | <1% | 211 | $1K | |
| 85610 | <1% | 621 | $1K | |
| 87077 | <1% | 1,857 | $1K | |
| 80076 | <1% | 211 | $1K | |
| 86803 | <1% | 100 | $1K | |
| 87210 | <1% | 519 | $914.23 | |
| 81001 | <1% | 1,412 | $890.88 | |
| 84439 | <1% | 1,523 | $832.27 | |
| 81003 | <1% | 1,019 | $759.05 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 384 | $710.97 |
| 82728 | <1% | 447 | $674.25 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 500 | $634.79 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 213 | $408.92 |
| 82950 | <1% | 599 | $387.61 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 204 | $372.51 |
| 85018 | <1% | 1,221 | $362.16 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 31 | $298.62 |
| 80164 | <1% | 163 | $260.78 | |
| 87420 | <1% | 16 | $229.20 | |
| 82652 | <1% | 31 | $189.28 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23 | $160.35 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14 | $151.20 |
| 83550 | <1% | 83 | $150.86 | |
| 84481 | <1% | 48 | $148.02 | |
| 86140 | <1% | 370 | $145.48 | |
| 85651 | <1% | 582 | $144.20 | |
| 82570 | <1% | 115 | $127.98 | |
| 86592 | <1% | 410 | $101.78 | |
| 82565 | <1% | 32 | $92.28 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13 | $91.38 |
| 82043 | <1% | 175 | $88.97 | |
| 82150 | <1% | 133 | $62.44 | |
| 83540 | <1% | 152 | $56.40 | |
| 84480 | <1% | 37 | $37.46 | |
| 84156 | <1% | 257 | $31.54 | |
| 86901 | <1% | 43 | $27.58 | |
| 87340 | <1% | 75 | $26.28 | |
| 82947 | <1% | 93 | $26.24 | |
| 83735 | <1% | 27 | $25.53 | |
| 86900 | <1% | 41 | $10.23 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 274 | $0.00 |
| 84520 | 0% | 32 | $0.00 | |
| 80347 | 0% | 207 | $0.00 | |
| 83992 | 0% | 30 | $0.00 | |
| 80361 | 0% | 19 | $0.00 | |
| 80365 | 0% | 19 | $0.00 | |
| 80364 | 0% | 270 | $0.00 | |
| 80345 | 0% | 27 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 282 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 255 | $0.00 |
| 80353 | 0% | 30 | $0.00 | |
| 80349 | 0% | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMALAS, JOSEPH (CFO)
Parent organizationMERCY HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Mercy Health System Corporation | Janesville, WI | $25.46M |
| Genesis Health System | Davenport, IA | $23.22M |
| Mercy Health System Corporation | Janesville, WI | $13.19M |
| Mercy Health System Corporation | Lake Geneva, WI | $9.39M |
| Mercy Health System Corporation | Janesville, WI | $8.15M |
| Mercy Assisted Care, INC | Janesville, WI | $4.04M |
| Genesis Medical Center, Aledo | Aledo, IL | $3.62M |
| Javon Bea Hospital | Rockford, IL | $1.23M |
| Mercy Health System Corporation | Janesville, WI | $1.17M |
| Mercy Assisted Care, INC | Harvard, IL | $601K |
| Mercyhealth Visiting Nurses Association, INC | Rockford, IL | $251K |
| Javon Bea Hospital | Rockford, IL | $174K |
| Genesis Health System | De Witt, IA | $136K |
| Mercy Assisted Care, INC | Janesville, WI | $136K |
| Genesis Health System | Bettendorf, IA | $32K |
| Mercy Assisted Care, INC | Janesville, WI | $12K |
| Mercy Harvard Hospital INC | Harvard, IL | $10K |
| Rockford Health Physicians | Rockford, IL | $9K |
| Mercy Health System Corporation | Janesville, WI | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.